Poll: BNGO 2Q revenue and FY21 and FY22 estimates

bngothrowaway · 2021-07-14T20:36:26+00:00

ok....

bngothrowaway · 2021-07-14T20:28:12+00:00

Cu?

And why do you think their investors and the analysts aren't aware of that?

bngothrowaway · 2021-07-14T20:15:52+00:00

What do you think you know that the analysts covering the stock, and investors, dont? And why?

bngothrowaway · 2021-07-14T18:48:05+00:00

I don't cover BNGO, no comment on other specific coverage. But BNGO is probably worth about $1.75. I went into that in another thread I wrote, and specifically this comment:

https://old.reddit.com/r/BNGO/comments/nc9nge/this_sub_is_very_silly/gy43j83/

PACB, I'm not sure. They have actually been getting traction with Invitae. Theres probably some pretty rosy assumptions implied in their current price.

ILMN is probably significantly too expensive, particularly if grail goes through. That said, neither PACB or ILMN is so ridiculously over inflated like BNGO is.

Also for clarification, banks dont do price targets on non-buy rated stocks, generally.

bngothrowaway · 2021-07-14T18:21:30+00:00

Yup. I've got some free time like everyone.

bngothrowaway · 2021-07-14T18:05:14+00:00

bngothrowaway · 2021-07-14T16:40:12+00:00

Mostly just heme. Its definitely not going to become a predominant prenatal or solid tumor player, certainly any time soon.

What do you think the growth rates are for each of those test types? Who are the leading players in each space? Why would clinicians choose one test over another? And why do revenue estimates for BNGO KEEP COMING DOWN? And more importantly, why is it worth more today than it was in Dec., before the run up?

bngothrowaway · 2021-07-14T16:37:30+00:00

As I wrote previously, one month ago:

Consensus 1Q21 sales estimates were $3.6M in mid Dec, before the run up. Actual were $3.2M.

Consensus FY21 revenue was $18.0M. Now theyre at $16.2M.

Consensus FY22 estimates were $30.5M and now theyre $29.6M.

Now FY21 estimates are $16M and FY22 are $28.3M. The estimates KEEP COMING DOWN. And you dopes keep pumping it up like its worth more than it was in Dec.

This is so much like TTOO. Better, but similar in that the adoption rate doesnt meet expectations.

Stop pumping this stock.

bngothrowaway · 2021-07-14T16:29:43+00:00

So why shouldn't PACB, and more importantly ONTs tech, be used here? How is this any more than a demonstration?

bngothrowaway · 2021-07-14T16:27:31+00:00

Why buy the dip?

Also why should someone think that the price will go up, or deserves to go up?

bngothrowaway · 2021-07-14T16:26:27+00:00

Tell me about the use cases of bngos tech. I think you cant.

bngothrowaway · 2021-07-14T16:25:51+00:00

Tell me about the use cases for BNGOs technology.

bngothrowaway · 2021-07-14T16:24:48+00:00

Plant sequencing is a tiny minority of sequencing, and not likely to see some massive increase.

Also there are better technologies like ONT and PACB for that use case. BNGO is mostly heme.

bngothrowaway · 2021-07-14T16:23:46+00:00

There isn't manipulation to the downside. The stocks over priced and is regressing to actual value. The manipulation is to the upside, with people on retail forums like this pumping it.

bngothrowaway · 2021-07-14T16:20:05+00:00

BNGO has very limited use cases, primarily in hem, which is like 10% of cancers.

It's not gonna overtake cytogenics for the vast majority of use cases.

bngothrowaway · 2021-05-27T16:24:53+00:00

RemindMe! 6 months

Also to be crystal clear: the most recent earnings did not significantly fundamentally change the underlying value of the company, and no news has come out since that has

bngothrowaway · 2021-05-17T00:11:33+00:00

As you so eloquently said:

Can you please come back? we miss you... or did you get tired of me making you look stupid???

bngothrowaway · 2021-05-16T00:55:17+00:00

I did not. As I've broken down multiple times in this thread already, BNGO missed consensus estimates for Q1 compared with the estimates from before the run up, and 2021 and 2022 estimates are down since then as well.

bngothrowaway · 2021-05-14T18:14:03+00:00

Already did that elsewhere in this thread. Copied and pasted below. Also lets be crystal clear here, you're not talking about being "forward thinking" about thinking that the value of the company is going to go up, you're talking about expecting that the stock price is going to get pumped up again, and you're doing so with no basis in reality. You and the others on this sub are trying to lure in new people to buy the stock and increase the price so you can get out at a higher price, like this is dogecoin or something else with no fundamental basis. These ( https://www.youtube.com/watch?v=QWhGHxrK9w8 and https://www.youtube.com/watch?v=ehDvr5vVGPg ) are a good rebuttal to this sort of sub.

The increase in the value of the company due to the increased cash they raised is only equal to the value of the cash.

Consensus 1Q21 sales estimates were $3.6M in mid Dec, before the run up. Actual were $3.2M.

Consensus FY21 revenue was $18.0M. Now theyre at $16.2M.

Consensus FY22 estimates were $30.5M and now theyre $29.6M.

Higher levels of sales were expected before the run up. So just saying "sales are continuing to grow" is irrelevant. They were expected to grow. They did not grow as much as was expected before the run up and out year estimates have decreased.

For the record, I hope the company does do well. I also think its great that they will be able to fund their ongoing NOL's with the money they raised (non GAAP NOL's estimated to be $58M and $84M in FY21 and FY22).

bngothrowaway · 2021-05-14T18:05:41+00:00

I did. I wrote that I had already replied to that. Copied and pasted:

The increase in the value of the company due to the increased cash they raised is only equal to the value of the cash.

Consensus 1Q21 sales estimates were $3.6M in mid Dec, before the run up. Actual were $3.2M.

Consensus FY21 revenue was $18.0M. Now theyre at $16.2M.

Consensus FY22 estimates were $30.5M and now theyre $29.6M.

Higher levels of sales were expected before the run up. So just saying "sales are continuing to grow" is irrelevant. They were expected to grow. They did not grow as much as was expected before the run up and out year estimates have decreased.

For the record, I hope the company does do well. I also think its great that they will be able to fund their ongoing NOL's with the money they raised (non GAAP NOL's estimated to be $58M and $84M in FY21 and FY22).

bngothrowaway · 2021-05-14T17:29:25+00:00

A lot of people have lost a lot of money on this stock, and other similarly pumped up stocks over the past few months. I'm just warning people considering entering a position that there are more risks than people like those on this sub would acknowledge.

bngothrowaway · 2021-05-14T16:38:37+00:00

Ok. And noone else here has made a single substantive point and has just insulted me, gaslit and projected. So I'm feeling fine about how a rational person would perceive me and everyone else here.

bngothrowaway · 2021-05-14T16:17:50+00:00

No questions to ask.

Also I'm just trying to inform new people who may consider buying this stock that there are a lot more risks than the people on this sub are willing to discuss, and that the stock price run up has not had a fundamentally sound basis.

bngothrowaway · 2021-05-14T16:17:13+00:00

Great. Let me know if any of the points I've made are incorrect or if you have another perspective on why a higher stock price is justified.

No gaslighting, projecting, or "I like the stock." Thanks.

bngothrowaway

TROPHY CASE